The current evidence for the efficacy and tolerability of modafinil and armodafinil in treating narcolepsy

Introduction

Narcolepsy is a chronic neurological disorder caused by loss or dysfunction of orexin producing neurons in the lateral hypothalamus, resulting in excessive daytime sleepiness (EDS), cataplexy, and reduced quality of life. The worldwide prevalence of narcolepsy is approximately 25 – 50 per 100,000 people and its typical onset occurs during adolescence or early adulthood. Wake-promoting agents such as modafinil and armodafinil are widely used as first line pharmacological treatments for EDS. Modafinil is a racemic compound, while armodafinil is its R-enantiomer with a longer half-life. This difference means that modafinil is better suited to twice daily use whereas armodafinil may suit patients with longer lasting day time sleepiness. Given the long-term nature of narcolepsy treatment, evaluating the efficacy and tolerability of these two medications remains clinically important. This review aimed to synthesise current evidence on the effectiveness and safety of modafinil and armodafinil in adults with narcolepsy.

Methods

A systematic literature search was conducted using PubMed, Embase, and Scopus, and the search was last updated in April 2025. Search terms included synonyms for modafinil, armodafinil and narcolepsy, combined with efficacy and tolerability outcomes. Inclusion criteria were English language human studies focusing on adults with narcolepsy that reported efficacy or safety outcomes. Editorials, case reports and paediatric studies were excluded. Outcome measures included objective and subjective measures of sleepiness, cognitive performance, mood, quality of life, and adverse events.

Results

Following screening and full text assessment, 23 studies were included. In total these studies incorporated 3,185 participants. The mean or median age was between 33.8 and 48.0 years, and the time from diagnosis of narcolepsy was between 6.4 and 9.7 years. Both modafinil and armodafinil demonstrated consistent improvements in EDS in short and long-term treatment. Significant reductions in Epworth Sleepiness Scale scores and increased sleep latency on objective wakefulness tests were observed. Improvements were also reported in cognitive performance, fatigue, mood and health-related quality of life. The tolerance of both drugs documented in the wider literature aligns with our findings. Both drugs were generally well tolerated. The most frequently reported adverse events were headache, nausea and dizziness, which were predominantly mild to moderate. No major safety concerns or clinically significant changes in vital signs were identified. However, whilst the two drugs were similarly well tolerated, cardiovascular side effects such as palpitations were more frequent in armodafinil related studies.

Conclusions

Current evidence supports modafinil and armodafinil as effective and well tolerated treatments for EDS in narcolepsy, with additional benefits for cognition, mood and quality of life. Subtle differences between modafinil and armodafinil were found, such as an increased long term side effect profile with armodafinil and modafinil having a greater impact on EDS at higher doses. Continued research comparing long-term outcomes and positioning these agents alongside newer therapies will help optimise personalised treatment strategies for patients with narcolepsy.

References

No references